Emerging Targets in Bladder Cancer: EV Pembro, HER2, and ADC Therapies in Focus
In part three of the bladder cancer roundtable, Dr. Shilpa Gupta leads the panel on a discussion of the latest developments in bladder cancer treatments, focusing on antibody-drug conjugates and targeted therapies. The panel addresses the promising results of enfortumab vedotin combined with pembrolizumab and explores the role of HER2-targeted therapies, such as TDXD, in bladder cancer.
▶︎
Treatment of Muscle-Invasive Bladder Cancer: Perioperative Immunotherapy
▶︎
Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology Conference
▶︎
Emerging Therapies: Bispecifics, PARP Inhibitors, and Novel Radioisotopes
▶︎
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metast...
▶︎
Overcoming Treatment Challenges in Heavily Pretreated Prostate Cancer
▶︎
Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC
▶︎
She’s 12. She Sings Aretha Franklin… Until Simon TELLS Her to Do It Acapella! 😳
▶︎
Sir Keir Starmer RESIGNS: Rory and Alastair React
▶︎
How EV + Pembrolizumab is Changing Bladder Cancer Care
▶︎
Management of Non-Muscle Invasive Bladder Cancer
▶︎
Bladder Cancer: NON-Muscle Invasive (Superficial Bladder Cancer)
▶︎
Efficacy and toxicity considerations when selecting patients for ADCs
▶︎
8 Symptoms That Could Point to Bladder Cancer (Many Don't Know About)!
▶︎
2 - 6 Months to Live & the Cool Thing About Cancer
▶︎
Episode 41: ASCO Annual Meeting 2026 Commentary: Prostate Cancer
▶︎
Muscle Invasive Bladder Cancer
▶︎
What is targeted therapy? When is it needed?
▶︎
Choosing Between Abiraterone and Novel ARPIs: Practical Insights
▶︎
Krebs-Killer - diese 10 Nährstoffe schützen wirklich!
▶︎